SK pharmteco will participate at the CPHI 2023 in Barcelona and prepare a dedicated booth at the event. As a multi-modality CDMO with expertise in small molecule active pharmaceutical ingredients (APIs) and biopharmaceuticals, SK pharmteco aims to present its business competitiveness and actively pu
SK pharmteco continues its trajectory to become the leading multi-modality CDMO by announcing it is acquiring a controlling interest in Philadelphia-based cell and gene therapy CDMO Center for Breakthrough Medicines (CBM), a move that will expand SK pharmteco’s technical expertise, production capaci
SK Co., Ltd. announced on July 18 that it had selected Brain Asset Management as the preferred negotiating partner for capital raising (pre-IPO) of its contract development and manufacturing organization (CDMO) subsidiary SK pharmteco. The scale of the investment attraction is around 500 million dol
SK Inc., together with its life science affiliates including SK biopharmaceuticals and SK pharmteco, will hold a networking event to expand their global partnerships in the U.S., the world’s largest bio and pharmaceutical market. SK Inc. is the strategic investment holding company of Korea’s SK Grou
SK Inc.’s pharmaceutical and bio business is growing fast through a steady localization strategy. The company plans to expand its contract development and manufacturing organization (CDMO) business to cover cell and gene therapies (CGTs).SK Pharmteco, a CDMO subsidiary of SK Inc., is expected to rac
SK Inc., the holding company of SK Group, is increasing domestic production in order to increase its presence in the global pharmaceutical contract development and manufacturing (CDM) market.SK Biotek announced on Oct. 4 that its new facilities in Sejong City were put into operation last month. SK B
SK Group chairman Chey Tae-won stressed the group's increasing investments in the U.S. and commitment to advancing sustainability as he hosted officials in Washington, D.C., for SK Night on Sept. 21 (local time). The event, the third SK Night, was held to showcase the group's growing U.S. pr
SK Pharmteco, SK Inc.’s contract development and manufacturing organization (CDMO) affiliate, announced its “Vision 2025” growth strategy at the 40th J.P Morgan HealthCare Conference on Jan. 10.SK Pharmteco took part in the Private Track for non-public companies at its first J.P Morgan HealthCare Co
SK Group has entered the U.S. cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) market. It has entered both the European and U.S. CGT CDMO markets.SK Inc., the group's holding company, announced on Jan. 9 that it has become the second-largest shareholder of C
SK Group acquired a European gene and cell therapy (GCT) contract manufacturing organization (CMO) company in March. Now it is in talks to take over a U.S. company in the same business field.SK Inc., the group’s holding company, announced on Nov. 16 that it was in exclusive talks with the Center for
U.S. pharmaceutical ingredient manufacturer AMPAC Fine Chemicals is planning to expand its facilities in the United States by investing up to US$25 million. The idea is to enhance its competitiveness in the field of contract development and manufacturing by strengthening its R&D functions and increa
SK Group is stepping up its efforts to tap into the European biopharmaceutical market. SK Biopharmaceuticals has been given the green light to sell its new drug Cenobamate in Europe. The group has also completed the acquisition of French contract manufacturing organization (CMO) company Yposkesi.SK
SK Holdings is currently seeking to acquire a promising biotech contract manufacturing organization (CMO) company in France.SK Holdings’ biotech and pharmaceutical business has been led by two companies –- SK Biopharm, a subsidiary in charge of developing new drugs, and SK Pharmteco in charge of the
SK Holdings will enter the bio-medicine contract manufacturing organization (CMO) business in earnest by acquiring a French CMO company.SK Pharmteco, SK Holdings’ CMO subsidiary is in negotiations to acquire Yposkesi, a French gene and cell therapy CMO company. Yposkesi is known to have platform tec
SK Group is expanding its contract manufacturing organization (CMO) business in earnest as the CMO market is growing fast due to the novel coronavirus crisis.SK Group has established itself as one of the three frontrunners of the Korean CMO industry, with the two others being Celltrion and Samsung B
South Korea’s foreign direct investment (FDI) in the United States topped US$10 billion for the fourth consecutive year with an increasing number of South Korean companies running their manufacturing facilities in the United States. According to Reshoring Initiative, the United States’ manufacturing
SK Group has decided to integrate its contract manufacturing organizations (CMOs) in South Korea, Europe and the United States.SK Holdings Co., the group’s holding company, announced on Sept. 2 that its board approved on Aug. 30 a plan to set up SK Pharmteco in Sacramento, California by integrating
SK Holdings Co., the holding entity of SK Group, has made SK Biotek’s overseas subsidiaries – SK Biotek Ireland Ltd. and SK Biotek USA Inc. – its own subsidiaries. SK Biotek, a pharmaceutical contract development and manufacturing organization (CDMO), is also an affiliate of SK Holdings. Experts say
SK Hynix Inc. is expected to see its operating profit account for more than 80 percent of the total of SK Group this year. As the group is becoming more and more dependent on the semiconductor business, it is getting more and more vulnerable as a whole. Market experts say that it is urgent for the g
Korean refineries and chemical companies are turning their attention to the bio-pharmaceutical market. Experts say that now is the right time for these companies to invest in biotech, a major future growth engine, as they have accumulated enough profits from their prosperous businesses.The SK Group